SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Merus N.V. (MRUS) , forward earnings yield 0.19%. PEG 0.17 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.17); analyst target implies upside (+22.2%).
- Forward P/E 516.4
- PEG Ratio 0.17 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $110.00 (+22.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MRUS
Valuation Multiples
P/E (TTM)0.0
Forward P/E516.4
PEG Ratio0.17
Forward PEG0.17
P/B Ratio0.00
P/S Ratio159.96
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.35
Forward EPS (Est.)$0.17
Book Value / Share$0.00
Revenue / Share$0.56
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.19%
Dividend Yield0.00%
Analyst Target$110.00 (+22.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1.65 |
$1.44M |
$-25.35M |
-1763% |
| 2016 |
$-3.75 |
$2.86M |
$-49.67M |
-1737% |
| 2017 |
$-4.57 |
$14.88M |
$-87.69M |
-589.2% |
| 2018 |
$-1.25 |
$35.97M |
$-27.76M |
-77.2% |
| 2019 |
$-2.28 |
$31.13M |
$-55.15M |
-177.1% |
| 2020 |
$-2.92 |
$29.94M |
$-85.51M |
-285.6% |
| 2021 |
$-1.73 |
$49.11M |
$-66.82M |
-136.1% |
| 2022 |
$-2.92 |
$41.59M |
$-131.19M |
-315.5% |
| 2023 |
$-3.00 |
$43.95M |
$-154.94M |
-352.6% |
| 2024 |
$-3.35 |
$36.13M |
$-215.33M |
-595.9% |
